A randomized controlled study for the safety and efficacy of autologous adipose-derived stromal vascular fraction in the treatment of acetabular labrum injury

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069624

Enrollment

Unknown

Registered

2023-03-22

Start date

2023-03-22

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acetabular labrum injury

Interventions

SVF Group:SVF treatment

Control Group:Intraarticular injection of lidocaine+diprosone into the hip joint

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients with hip pain and limited movement, diagnosed with acetabular labrum on imaging examination, and with unsatisfactory effect after conservative treatment for 3-6 months; (2) Hip osteoarthritis Tonnis grade <=2; (3) Patients at least 18 years old; (4) Patients who agree to receive an injection of lidocaine + Dubossone in the hip joint (control group) and an autologous SVF injection (experimental group).

Exclusion criteria

Exclusion criteria: (1) The patient under 18 years old; (2) The affected hip has received previous surgery; (3) The affected hip complicates with fracture, femoral head necrosis, joint tuberculosis, joint adhesion, etc.; (4) Hip osteoarthritis Tonnis grade > 2; (5) Patients with pregnant, significantly abnormal blood coagulation, low immunity, joint cancer or infection and other special groups.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale;Modified Harris Hip Score;nonarthritic hip score;subjective satisfaction;healing of acetabular labrum;	—

Countries

China

Contacts

Public ContactWang Jianquan

Peking University Third Hospital

kenyl417@vip.sina.com+86 010-82265680

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026